You have been told for years that hot flashes and broken sleep are just the price of being a woman your age. That advice is outdated, and you already know it — this is a look at how a modern provider actually thinks through the decision.
The fear you were handed — and what changed
Most of the hesitation around menopausal hormone therapy traces back to headlines from the Women's Health Initiative (WHI) in the early 2000s. Those early reports, read without nuance, scared a generation of women — and their doctors — away from hormones entirely.
What followed was decades of re-analysis. A clearer picture emerged: risk and benefit depend heavily on *who* is starting hormones, *when*, and *which formulation* [1][2]. The North American Menopause Society (now The Menopause Society) and the Endocrine Society both now describe menopausal hormone therapy as a reasonable option for many symptomatic women, especially those who begin closer to the onset of menopause rather than many years out [1][2]. This is often called the "timing hypothesis."
This is educational information, not medical advice. Whether hormone therapy fits your health history is a decision only an independent licensed provider can make with you.
Why the uterus is the first question, not an afterthought
Here is the mechanism that drives the whole plan. Estrogen stimulates the growth of the endometrium — the lining of the uterus. Given alone in a woman who still has her uterus, that unopposed stimulation raises the risk of endometrial overgrowth (hyperplasia) and, over time, endometrial cancer [3].
Progesterone — or a progestin — is what counterbalances that effect. It shifts the lining away from continuous growth and protects it. This is why, for a woman with an intact uterus, a provider almost never considers estrogen in isolation. The two are considered as a pair for endometrial protection [1][3].
If a woman has had a hysterectomy, the calculus is different — the endometrial-protection reason for adding a progestogen is generally no longer present, and estrogen-only therapy may be discussed [1]. That single fact — do you still have your uterus — reshapes the entire conversation.
"Which one first?" is the wrong frame
Many women arrive expecting a strict sequence: estrogen first, then progesterone, or the reverse. In practice, a provider is usually thinking about how the two are *combined* over a monthly cycle, not a rigid start order.
Broadly, there are two combined patterns a provider may consider for a woman with a uterus [1][3]:
- Continuous combined — estrogen and a progestogen taken together on an ongoing basis.
- Sequential (cyclic) — estrogen ongoing, with the progestogen added for part of each cycle, which can produce a scheduled withdrawal bleed.
Which pattern a provider leans toward often depends on how many years past your final period you are. Women who are several years into menopause — where you are at 56 — are frequently considered for continuous combined approaches, because a return of monthly bleeding is usually not welcome. The choice is individualized, and it is the provider's call, made with your history in front of them.
Route and form matter as much as the molecule
Estrogen can be delivered by mouth or through the skin (transdermal patches, gels). This is not a cosmetic distinction. Oral estrogen passes through the liver first, which influences clotting factors; transdermal estrogen largely bypasses that first pass. Professional guidance notes that transdermal routes are often considered when a provider is weighing clot risk [1][2].
On the progestogen side, there is a meaningful difference between micronized progesterone (structurally identical to what the body makes) and synthetic progestins. Some evidence suggests these are not interchangeable in their risk profiles, which is why a provider chooses deliberately rather than by default [1][2].
A note on compounded hormones: some products marketed as "bioidentical" are custom-compounded. Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state. The National Academies has specifically cautioned that compounded hormone therapy is often used without the evidence base that supports approved products [4]. A prescription of any kind is never guaranteed; it is decided by an independent licensed provider.
Source: [1] The 2022 Hormone Therapy Position Statement of The North American Menopause Society, [2] Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline
Is it "too late" at 56?
This is the question that keeps many capable women toughing it out. The honest answer from current guidance: age and years-since-menopause both matter, but being in your mid-fifties and a few years post-menopause does not automatically close the door [1][2].
What a provider generally weighs is the balance of your symptoms against your personal risk factors — cardiovascular history, clotting history, breast health, and more. Guidance frames the most favorable benefit-risk window as generally within about ten years of menopause onset or under age 60, while emphasizing that this is a starting point for a personalized discussion, not a hard cutoff [1]. The point is not a rule; it is that the conversation is worth having rather than assuming you missed your chance.
years since menopause onset · marker = Several years post-menopause at 56
Source: [1] The 2022 Hormone Therapy Position Statement of The North American Menopause Society
What the first weeks can involve
Starting hormone therapy is a process, not a single event. Without any dosing specifics — that is entirely the provider's domain — here is the general shape of the early period.
A provider typically begins with a baseline review: symptoms, personal and family history, and often screening such as blood pressure and up-to-date breast and pelvic screening as clinically appropriate [1][3]. From there, any regimen is introduced and monitored. Early on, some women notice their body adjusting — breast tenderness, mood shifts, or, with sequential regimens, scheduled bleeding are among the adjustments guidance describes as possible during this phase [3]. A follow-up window is standard, so the provider can reassess and adjust.
Unexpected or persistent bleeding is something to report promptly, because it can prompt further evaluation of the endometrium [3]. This is exactly why ongoing provider contact matters more than any single starting decision.
Source: [1] The 2022 Hormone Therapy Position Statement of The North American Menopause Society, [3] ACOG Practice Bulletin: Management of Menopausal Symptoms
What you can bring to the conversation
You run a school. You are used to walking into a room prepared. Bring the same rigor here: a symptom timeline, your surgical history (especially whether you still have a uterus), your family history of breast cancer and blood clots, and your current medications. A provider who respects current science will want that detail — it is the raw material for an individualized plan rather than a one-size template.
Where Velri fits
Velri is a non-clinical technology and coordination company — we do not provide medical care. What we do is make the modern conversation easier to have. Velri can coordinate appropriate lab work, connect you with an independent, licensed provider for an evaluation of your history and goals, and — *if* that provider prescribes — coordinate with an independent licensed pharmacy for fulfillment. Whether hormone therapy is appropriate, and in what form, is always the independent provider's decision, not Velri's, and a prescription is never guaranteed. This article is educational and is not medical advice.
